Verastem reported $-44.9M in EBIT for its fiscal quarter ending in March of 2026.





Ebit Change Date
AbbVie USD 6.88B 156M Sep/2026
Alaunos Therapeutics USD -952K 60K Jun/2026
AstraZeneca USD 4.66B 1.5B Sep/2026
Curis USD -11.52M 3.64M Mar/2026
Cytokinetics USD -167.09M 12.08M Sep/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
Incyte USD -707.47M 1.41B Sep/2026
Laboratory Of America USD 418M 38.7M Sep/2026
Novartis USD 5.14B 411M Sep/2026
Pfizer USD 4.85B 5.03B Sep/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
TG Therapeutics USD 85.9M 64.22M Sep/2026
Verastem USD -44.9M 3.42M Mar/2026